Staphylococcus aureus News and Research RSS Feed - Staphylococcus aureus News and Research

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.
FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). [More]
Researchers find that humans carry more antibiotic-resistant staphylococci than farm animals

Researchers find that humans carry more antibiotic-resistant staphylococci than farm animals

Antibiotic-resistant bacteria are a concern for the health and well-being of both humans and farm animals. One of the most common and costly diseases faced by the dairy industry is bovine mastitis, a potentially fatal bacterial inflammation of the mammary gland (IMI). Widespread use of antibiotics to treat the disease is often blamed for generating antibiotic-resistant bacteria. [More]
Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Last year, a Wyss Institute team of scientists described the development of a new device to treat sepsis that works by mimicking our spleen. It cleanses pathogens and toxins from blood circulating through a dialysis-like circuit. Now, the Wyss Institute team has developed an improved device that synergizes with conventional antibiotic therapies and that has been streamlined to better position it for near-term translation to the clinic. [More]
Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too. [More]
Contact precaution use needs to be individualized to fit hospital's specific needs and resources

Contact precaution use needs to be individualized to fit hospital's specific needs and resources

Contact precautions are recommended by the Centers for Disease Control and Prevention for all patients known to be infected with or carrying multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Yet, the use of contact precautions--which require a patient to be isolated in a single hospital room and health care providers to wear a gown and gloves when caring for patients--is widely debated in the medical community. [More]
Duke specialist offers infection control measures to maintain health of pro football players

Duke specialist offers infection control measures to maintain health of pro football players

Keeping any team healthy is an important and daunting challenge, but the task is amplified in the National Football League when a bug that spreads rapidly through locker rooms and training facilities can impact an entire season. [More]
Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium reports net loss of $4.0 million for second quarter 2015

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015. [More]

AmpliPhi provides update on cGMP manufacturing facility and investigational bacteriophage cocktail for treating S. aureus

AmpliPhi BioSciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash. [More]
Coordinated, two-part approach could help reduce hospital-acquired infections

Coordinated, two-part approach could help reduce hospital-acquired infections

By coordinating with state health departments and communicating with each other about patients with C. difficile and antibiotic-resistant infections, hospitals, long-term acute-care facilities and nursing homes could reduce the number of such hospital-acquired infections (HAIs) by an estimated 619,000 cases in the next five years, a new Centers for Disease Control 9 (CDC)-led report has found. [More]
IU scientists find evidence that invisible war between microorganisms may affect human health

IU scientists find evidence that invisible war between microorganisms may affect human health

Health experts have warned for years that the overuse of antibiotics is creating "superbugs" able to resist drugs treating infection. [More]
Hospitals can make patients sick, reveals Consumer Reports

Hospitals can make patients sick, reveals Consumer Reports

Hospitals are thought to be sterile, safe environments where sick people get better, not sicker. But that's not always the case according to a new investigation by Consumer Reports into hospital-acquired infections. [More]
Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. [More]
Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [More]
Kenall Manufacturing introduces light fixture to kill harmful bacteria linked to HAIs

Kenall Manufacturing introduces light fixture to kill harmful bacteria linked to HAIs

Kenall Manufacturing today introduced Indigo-Clean, a light fixture that uses Continuous Environmental Disinfection technology to continuously kill harmful bacteria linked to hospital acquired infections (HAIs). The technology behind Indigo-Clean inactivates a wide range of micro-organisms that are known causes of HAIs, including MRSA (Methicillin-resistant Staphylococcus aureus), C.difficile and VRE (Vancomycin-resistant Enterococcus). [More]
Daily CHG bathing protocol for pediatric patients reduces bloodstream infections by 59%: Study

Daily CHG bathing protocol for pediatric patients reduces bloodstream infections by 59%: Study

Daily bathing of pediatric patients with disposable cloths containing 2 percent chlorhexidine gluconate (CHG) reduced central line-associated bloodstream infections (CLABSIs) by 59 percent and saved approximately $300,000 in one hospital over a six-month period, according to a new study. [More]
World MRSA Day Kickoff Event and Global C. difficile Summit to be held on September 26, 2015 in Illinois

World MRSA Day Kickoff Event and Global C. difficile Summit to be held on September 26, 2015 in Illinois

Methicillin-resistant Staphyloccocus aureus (MRSA), the antibiotic resistant form of Staphylococcus aureus is rampant in U.S. healthcare facilities, in the community, in livestock and in the environment. [More]
Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia. [More]

Dipexium Pharmaceuticals intends to sell common stock in underwritten public offering

Dipexium Pharmaceuticals, Inc., a late stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), today announced it intends to offer and sell common stock in an underwritten public offering. [More]
Survey finds first evidence of MRSA in sausages, minced pork from supermarkets in the UK

Survey finds first evidence of MRSA in sausages, minced pork from supermarkets in the UK

A survey carried out earlier this year has found the first evidence of the 'superbug' bacteria Methicillin-Resistant Staphylococcus aureus (MRSA) in sausages and minced pork obtained from supermarkets in the UK. However, researchers stress that this does not pose a significant immediate risk to the public. [More]
Study suggests new strategies to stop spread of Staph infections

Study suggests new strategies to stop spread of Staph infections

Staphylococcus aureus -- better known as Staph -- is a common inhabitant of the human nose, and people who carry it are at increased risk for dangerous Staph infections. [More]
Advertisement
Advertisement